Control was 50mg mannitol twice daily for 52 weeks, as opposed to 400mg twice daily for treatment dose.
Has this contributed to it missing statistical significance? Wasn't this also an issue in the CF trials?
Another case of poor trial design?
Held this stock for 7 years. What a waste of time and money!
ph 3 trial fails primary endpoint, page-6
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $39.40M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 3.2¢ | $46.51K | 1.381M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 186766 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 196199 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |